Indian stocks: Visit www.stage2stocks.com →

Tvardi Therapeutics, Inc.

Stage 4 · Declining · week 35

As of Oct 22, 2026, Tvardi Therapeutics is in Stage 4, the downtrend phase, now in week 35 (since Feb 19, 2026). It closed at $0.97, 81.4% below its 52-week high and below its 200-day average, which is falling.

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcriptio… More about the company

$0.97
-6.54% today
$13.0M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is TVRD early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 31w
S4 18w
S2 24w
S4 35w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 31w → S1 8w → S4 18w → S1 1w → S4 12w → S1 9w → S2 24w → S3 4w → S2 7w → S3 3w → S4 12w → S1 2w → S4 35w current
Total tracked: 166 weeks across 13 stage runs.

TVRD among Biotechnology480th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…480TVRDStage 4 · wk 3510−26.4%
vs 52W High
-81.4%
$0.97 lo$5.23 hi
81.4% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 35
1w13w26w
Week 35, extended decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-66.1%
200 DMA: $2.87 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.31x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-26.4%
3M
-61.3%
6M
-67.7%
YTD
-76.2%
1Y
-83.0%
Scan Membership
Breakout Watch
Latest: 2025-02-19
6 appearances in last 60 days. First seen: 2018-10-16.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 35 · Vol 0.31x
2026-10-21S4
Wk 34 · Vol 0.74x
2026-10-20S4
Wk 34 · Vol 1.05x
2026-10-19S4
Wk 34 · Vol 1.10x
2026-10-16S4
Wk 34 · Vol 0.48x
2026-10-15S4
Wk 34 · Vol 0.48x
2026-10-14S4
Wk 33 · Vol 0.37x
2026-10-13S4
Wk 33 · Vol 0.36x
2026-10-12S4
Wk 33 · Vol 1.21x
2026-10-09S4
Wk 33 · Vol 0.63x
2026-10-08S4
Wk 33 · Vol 0.73x
2026-10-07S4
Wk 32 · Vol 0.60x
Moving averages & range
50 DMA
$1.50
200 DMA
$2.87
52W High
$5.23
52W Low
$0.97
5D Low
$0.97
Resistance levels (recent highs)
20d High
$1.33
60d High
$2.10
120d High
$5.00
250d High
$5.00
Next resistance
+36.8%
to 20d High
ROE
-126.2%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 1.1

Tvardi Therapeutics: quick answers

What stage is Tvardi Therapeutics in?

As of Oct 22, 2026, Tvardi Therapeutics (TVRD) is in Stage 4, the downtrend phase. It entered Stage 4 on Feb 19, 2026 and is in week 35. What the four stages mean

Is Tvardi Therapeutics in an uptrend?

No. Tvardi Therapeutics is in a Stage 4 downtrend. It trades 66.1% below its 200-day average, which is falling.

How far is Tvardi Therapeutics from its 52-week high?

Tvardi Therapeutics closed at $0.97 on Oct 22, 2026, 81.4% below its 52-week high of $5.23. Its 52-week low is $0.97.

How has Tvardi Therapeutics performed over the past year?

As of Oct 22, 2026, Tvardi Therapeutics is down 83.0% over the past year and down 76.2% so far in 2026.

Which sector and industry is Tvardi Therapeutics in?

Tvardi Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.